SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Zwiener who wrote (84)2/5/1997 12:33:00 AM
From: James Silverman   of 1115
 
More food for you John. I had been trying to urge you to do a little HW in so many words, to no avail.

Forvade is not antisense but a viral polymerase inhibitor. Viral polymerase synthesizes the DNA of the VIRUS, much the same way Reverse Transcriptase synthesizes the RNA of HIV (RNA because HIV is a retrovirus). Gilead has novel nucleoside phosphonates mimics which do not need to be phosphorylated in-vivo like acyclovir which requires an enzyme to phosphorylate it. This phosphorylaltion step can be rate-limiting in the action of the drug. Their compounds are unique from other viral p and RT inhibs due to this phosphoryl mimic on the drug. Gilead still has this old image of antisense which is no longer the focus, take a look at them and you will see this is indeed the case as they have a world class antiviral r&d, perhaps unmatched in the entire pharmaceutical industry.

John, Forvade acts just like the approved drug acyclovir so I don't see a problem with it. Plus, as stated previously it is an analog of its approved drug, Vistide. As I hope I have shown loud and clear, this time, your logic as to why Forvade is unapprovable makes no sense.
Next time you desire to hurl insults my way, please spare me. They only proved to show glaring holes in your research.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News